Sanofi goes deeper into the lead
The French group takes a shot at Perspective with its second bet on Orano Med.
The French group takes a shot at Perspective with its second bet on Orano Med.
The company’s CEACAM5 and PRMT5 projects feature among the latest first-in-human entrants.
Patients' expression of CEACAM5 might hold the key to activity after all.
It’s back to school for biotech, with a packed conference schedule.
Darzalex added another string to its bow, while Kisqali’s early use has been delayed.
The companies hopes to be as efficacious as ex vivo therapy, with convenience and safety advantages.
The companies’ PD-(L)1 x VEGF bispecifics will clash in triple-negative breast cancer.